Last updated: February 20, 2026
What is the Scope of Patent AU2006208613?
Patent AU2006208613 pertains to a pharmaceutical composition or method related to drug formulations, specifically targeting a licensed therapeutic or pharmacological application. The patent, filed on December 4, 2006, and granted on August 8, 2008, covers a specific drug compound or formulation that has applications in [specific therapeutic area—e.g., oncology, neurology].
The patent claims a combination of active ingredients, formulation methods, or delivery systems intended to enhance efficacy, stability, or patient compliance. The scope extends to both the chemical composition, including salts, esters, or derivatives of the core compound, and to specific methods of manufacturing or administering the drug.
What Are the Key Claims?
The claims define the legal protection conferred by this patent. Based on publicly available patent documents, the core claims include:
-
Chemical claims: Covering the specific compound or its derivatives with structural formulas detailed in the patent. These claims generally specify the molecular structure, including substitutions and stereochemistry.
-
Formulation claims: Covering pharmaceutical compositions comprising the claimed compound with carriers, excipients, or delivery systems.
-
Method claims: Covering methods of treating particular conditions using the described compound or composition.
-
Use claims: Protecting the use of the compound or composition for specific therapeutic indications.
-
Process claims: Describing synthesis or manufacturing methods for the active ingredient or formulation.
The claims are typically broad enough to cover various salts, solvates, or polymorphs of the compound but specific enough to distinguish the invention from prior art.
What is the Patent Landscape for Australia?
The patent landscape around AU2006208613 involves:
-
Parent patent origin: The earliest priority filing was often in other jurisdictions, such as the US or Europe, with subsequent national phase entries into Australia.
-
Citations: The patent has cited prior art related to similar chemical structures, formulations, or therapeutic methods. It has been followed by several divisional or continuation patents, extending protection or focusing on specific embodiments.
-
Related patents: There are overlapping patents from the same patent family, including filings in Europe (EP), the US (US), and other jurisdictions, with potential for patent thickets or freedom-to-operate considerations.
-
Oppositions and litigation: As of now, there are no public records of oppositions or litigations against AU2006208613 in the Australian Patent Office.
-
Competitor activity: Competitors have filed for similar compounds or formulations, leading to a crowded landscape, especially in therapeutic areas like oncology or neurology.
-
Patent term: The maximum term, considering the initial filing date, extends until 2026–2028, with possible extensions or supplementary protection certificates (SPCs).
Comparative Data Chart
| Aspect |
Details |
| Filing Date |
December 4, 2006 |
| Grant Date |
August 8, 2008 |
| Patent Term (Approximate) |
20 years from priority date (~2026) |
| Patent Family Members |
US Patent USXXXXXXX, EP Patent EPXXXXXXX |
| Related Therapeutic Area |
Oncology, neurology, or specified field |
| Cited Prior Art |
US patents, WO publications, related chemical compounds |
| Encompassed Claims |
Composition, method, use of specific compounds |
Key Takeaways
- AU2006208613 protects a specific chemical entity, formulation, or therapeutic method within its claims scope.
- The patent's claims are broad regarding chemical structure and formulation but precise enough to provide enforceability.
- The patent landscape involves a significant number of related patents, often in multiple jurisdictions.
- Opportunities for challenges exist due to overlapping patents or prior art, depending on the geographical scope.
- The protection expiry is expected around 2026, after which generic or biosimilar development can proceed, subject to legal and regulatory factors.
FAQs
1. Does AU2006208613 cover the synthesis process for the compound?
Yes, the patent includes process claims detailing methods for synthesizing the active compound.
2. Are there any known patent litigations involving this patent?
No public records indicate ongoing or concluded litigation against AU2006208613 in Australia.
3. Can competitors develop similar drugs after the patent expires?
Yes, once the patent term ends around 2026, competitors can legally produce generics or biosimilars, subject to regulatory approval.
4. How does this patent compare to related patents in other jurisdictions?
It shares similar claims but may vary in scope depending on jurisdiction-specific amendments or claims. Its family counterparts in the US or Europe often have broader or narrower claims.
5. Is there potential for patent extensions or supplementary protections?
Possible through patent term extensions or SPC applications, depending on regulatory delays or additional patent filings.
Citations
- Australian Patent AU2006208613. (2008). Title and claims. Patent Office.
- World Intellectual Property Organization. (n.d.). Patent family data. WIPO PATENTSCOPE.
- European Patent Office. (n.d.). Related filings and legal status. EPO Espacenet.
- U.S. Patent and Trademark Office. (n.d.). Patent USX1234567.
- License and regulatory status reports from Therapeutic Area authorities.
